Pfizer, BioNTech seek to extend COVID-19 vaccine use to adolescents in EU

The application to extend the marketing authorisation for use in adolescents aged 12-15 (currently approved for use in people from 16 years of age) is based on data from a Phase III study (n=2,260) showing an efficacy of 100% and robust antibody responses.

Source:

Reuters Health